WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561166

CAS#: 1010694-08-2

Description: EC-19 induce the differentiation of EC cells. EC-19 directs the cells to form epithelial-like derivatives.

Price and Availability




EC-19 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 561166
Name: EC-19
CAS#: 1010694-08-2
Chemical Formula: C23H24O2
Exact Mass: 332.1776
Molecular Weight: 332.443
Elemental Analysis: C, 83.10; H, 7.28; O, 9.63

Synonym: EC-19; EC19; EC 19

IUPAC/Chemical Name: 3-[2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethynyl]benzoic acid


InChi Code: InChI=1S/C23H24O2/c1-22(2)12-13-23(3,4)20-15-17(10-11-19(20)22)9-8-16-6-5-7-18(14-16)21(24)25/h5-7,10-11,14-15H,12-13H2,1-4H3,(H,24,25)

SMILES Code: O=C(O)C1=CC=CC(C#CC2=CC=C3C(C)(C)CCC(C)(C)C3=C2)=C1

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Kurz SG, Hazra S, Bethel CR, Romagnoli C, Caselli E, Prati F, Blanchard JS, Bonomo RA. Inhibiting the β-Lactamase of Mycobacterium tuberculosis (Mtb) with Novel Boronic Acid Transition-State Inhibitors (BATSIs). ACS Infect Dis. 2015 Jun 12;1(6):234-42. doi: 10.1021/acsinfecdis.5b00003. Epub 2015 Apr 15. PubMed PMID: 27622739.

2: Lopez-Real RE, Budge JJ, Marder TB, Whiting A, Hunt PN, Przyborski SA. Application of synthetic photostable retinoids induces novel limb and facial phenotypes during chick embryogenesis in vivo. J Anat. 2014 Apr;224(4):392-411. doi: 10.1111/joa.12147. Epub 2013 Dec 4. Erratum in: J Anat. 2014 Apr;224(4):529. J Anat. 2014 Apr;224(4):529. PubMed PMID: 24303996; PubMed Central PMCID: PMC4098675.

3: Clemens G, Flower KR, Henderson AP, Whiting A, Przyborski SA, Jimenez-Hernandez M, Ball F, Bassan P, Cinque G, Gardner P. The action of all-trans-retinoic acid (ATRA) and synthetic retinoid analogues (EC19 and EC23) on human pluripotent stem cells differentiation investigated using single cell infrared microspectroscopy. Mol Biosyst. 2013 Apr 5;9(4):677-92. doi: 10.1039/c3mb25505k. PubMed PMID: 23364809.

4: Beceiro A, Maharjan S, Gaulton T, Doumith M, Soares NC, Dhanji H, Warner M, Doyle M, Hickey M, Downie G, Bou G, Livermore DM, Woodford N. False extended-spectrum {beta}-lactamase phenotype in clinical isolates of Escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins. J Antimicrob Chemother. 2011 Sep;66(9):2006-10. doi: 10.1093/jac/dkr265. Epub 2011 Jul 8. PubMed PMID: 21742679.

5: Maltman DJ, Christie VB, Collings JC, Barnard JH, Fenyk S, Marder TB, Whiting A, Przyborski SA. Proteomic profiling of the stem cell response to retinoic acid and synthetic retinoid analogues: identification of major retinoid-inducible proteins. Mol Biosyst. 2009 May;5(5):458-71. doi: 10.1039/b817912c. Epub 2009 Mar 12. PubMed PMID: 19381361.

6: Williams DR, Kiryanov AA, Emde U, Clark MP, Berliner MA, Reeves JT. Studies of stereocontrolled allylation reactions for the total synthesis of phorboxazole A. Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12058-63. Epub 2004 Jul 26. PubMed PMID: 15277662; PubMed Central PMCID: PMC514434.